Childhood Glaucoma
Childhood glaucoma is a rare condition that may be inherited, caused by incorrect development of the eye’s drainage system before birth.
Menu
Menu
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
Childhood glaucoma is a rare condition that may be inherited, caused by incorrect development of the eye’s drainage system before birth.
Both cataracts and glaucoma can be a natural part of the aging process. Many people over 60 may have both.
One way to help prevent vision loss from glaucoma is to make sure you get regular eye examinations. Early diagnosis and treatment is critical to preserving sight.
“My advice for the blind community is to be prepared for what life may throw at you and be open to learn new things.” — Jasmyn Polite
Tonian strives to be a face for change and spread awareness of glaucoma in her country of Jamaica, and around the world.
“It’s always exciting to have new and effective treatment alternatives available to help patients,” said Andrew Iwach, MD.
After cataracts, glaucoma is the leading cause of blindness in African Americans. Half of those with glaucoma don’t know they have it.
Andrew Huberman, PhD is a principal investigator in the Catalyst for a Cure Biomarkers Team funded by Glaucoma Research Foundation in San Francisco, CA.
The Srinivasan Laboratory at the University of California, Davis, develops novel optical imaging techniques and diagnostics with applications spanning from basic to clinical research.
Dr. Goldberg’s glaucoma research is directed at neuroprotection and regeneration of retinal ganglion cells and other retinal neurons.
Retinal ganglion cells (RGCs) are particularly important in glaucoma because they are the cells that are damaged by the disease.
In November 2017, the FDA approved Vyzulta, latanoprostene bunod (LBN), as a potential game-changer in the treatment of glaucoma.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2022 all rights reserved.
Print Subscription
(The printed edition of the Gleams newsletter is only available if you live in the United States or Canada)
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.